Nassif Mikheal
Known title: CEOCIK: 0002082158
Nassif Mikheal's purchase track record
How the stock did after each of Nassif Mikheal's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 6 since November 3, 2025
Stock higher 6 months later
75%
3 months: 50%
Median 6-month return
+8.2%
3 months: -1.4%
Beat the S&P 500
50%
median -1.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/9/2026 | NEOG | $6K | pending | pending | — |
| 8/4/2026 | NEOG | $4K | pending | pending | — |
| 2/17/2026 | NEOG | $252 | -24.0% | +5.3% | +12.4% |
| 1/26/2026 | NEOG | $486 | -5.6% | -6.7% | +6.7% |
| 1/16/2026 | NEOG | $1K | +2.8% | +11.0% | +7.5% |
| 11/3/2025 | NEOG | $1K | +63.0% | +44.5% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NEOG | ▲ Buy | Open Market | 505 | $6K | 10/9/2026 | View on chart |
| NEOG | ▼ Sell | Tax Withholding | 20,397 | $242K | 8/19/2026 | View on chart |
| NEOG | ▲ Buy | Grant | 141,631 | $1.7M | 8/14/2026 | View on chart |
| NEOG | ▲ Buy | Open Market | 370 | $4K | 8/4/2026 | View on chart |
| NEOG | ▲ Buy | Open Market | 23 | $252 | 2/17/2026 | View on chart |
| NEOG | ▲ Buy | Open Market | 24 | $240 | 2/2/2026 | View on chart |
| NEOG | ▲ Buy | Open Market | 25 | $246 | 1/26/2026 | View on chart |
| NEOG | ▲ Buy | Open Market | 137 | $1K | 1/16/2026 | View on chart |
| NEOG | ▲ Buy | Open Market | 177 | $1K | 11/3/2025 | View on chart |
| NEOG | ▲ Buy | Grant | 414,365 | $2.3M | 8/15/2025 | View on chart |
| NEOG | ▲ Buy | Grant | 184,162 | $1000K | 8/15/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Neogen Corp reports earnings, faces FDA warning, outlines growth plan
Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.
Neogen Corp reports earnings, faces FDA warning, outlines growth plan. Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.